Alzheimer's Disease and Dementia
Featured Topics
Lead story
Other featured articles
-
Key Barriers for Clinical Trials for Alzheimer’s Disease
Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.
Posted in -
Research Spotlight: Alzheimer’s Disease
Schaeffer Center researchers are analyzing trends associated with a greying population, including AD prevalence and cost, and what these trends mean for society.
Posted in -
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for future advances in Alzheimer’s disease (AD) made in 2001 and projects future breakthroughs over the next 20 years.
Posted in -
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Posted in
About this section
Even small delays in the onset of Alzheimer's disease and dementia could have significant impacts for the patient, their family and caregivers, and the healthcare system more broadly. The Schaeffer Center's microsimulation models demonstrate there may be preventive measures we can take now to shape the nation's future health.
OUR EXPERTS ON ALZHEIMER'S DISEASE AND DEMENTIA PREVENTION
Our Work In Alzheimer's Disease and Dementia
-
After Decades of Disappointment, a Turning Point Is Visible in Alzheimer’s Treatment
The USC-Brookings Schaeffer Initiative for Health Policy hosted a webinar featuring national thought leaders to examine hopeful signs in clinical development and policy that will ensure access to treatments and diagnostics.
Categorized in -
Blood‐Based Biomarkers for Alzheimer’s Pathology and the Diagnostic Process for a Disease‐Modifying Treatment: Projecting the Impact on the Cost and Wait Times
Blood‐based biomarker tests are a promising tool to improve triaging Alzheimer’s disease at the primary care level.
Categorized in -
Overcoming Barriers to Success in Alzheimer’s Disease Clinical Trials
Even modest delays in the progression of Alzheimer’s disease could dramatically alter the current trajectory and generate large health benefits.
Categorized in -
Innovation in Alzheimer’s Disease: Policies to Support Access to Treatments, Diagnostics, and Prevention
Join the USC-Brookings Schaeffer Initiative for Health Policy for a webinar that looks at hopeful signs in clinical development and the policy challenges on how to make available Alzheimer’s disease treatments and diagnostics to all those who should have them.
Categorized in -
Sex, Race, and Age Differences in Prevalence of Dementia in Medicare Claims and Survey Data
This study provides the first comparison of trends in dementia prevalence in the U.S. population using 3 different dementia ascertainments/data sources. They found there are still substantial differences across measures in dementia prevalence among Blacks and Hispanics.
-
Association of Combination Statin and Antihypertensive Therapy With Reduced Alzheimer’s Disease and Related Dementia Risk
Drugs already being used to treat high blood pressure and cholesterol could reduce the risk of Alzheimer’s disease and dementia, according to a new Schaeffer Center study of nearly 700,000 Medicare beneficiaries.
Categorized in